Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Batirel, M. Metintaş, H. Çağlar, B. Yıldızeli, T. Lacin, K. Bostancı, A. Akgul, S. Evman, M. Yuksel (2008)
Trimodality Treatment of Malignant Pleural MesotheliomaJournal of Thoracic Oncology, 3
G. Murphy (1991)
The national cancer data baseCA: A Cancer Journal for Clinicians, 41
E. Miles, N. Larrier, C. Kelsey, J. Hubbs, Jinli Ma, S. Yoo, L. Marks (2008)
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.International journal of radiation oncology, biology, physics, 71 4
Glenn Steele, David Winchester, H. Menck (1994)
The national cancer data base. A mechanism for assessment of patient careCancer, 73
V. Rusch, K. Rosenzweig, E. Venkatraman, L. Leon, A. Raben, L. Harrison, M. Bains, R. Downey, R. Ginsberg (2001)
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.The Journal of thoracic and cardiovascular surgery, 122 4
R. Flores, L. Krug, K. Rosenzweig, E. Venkatraman, A. Vincent, R. Heelan, T. Akhurst, V. Rusch (2006)
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II TrialJournal of Thoracic Oncology, 1
E. Taioli, A. Wolf, R. Flores (2015)
Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.The Annals of thoracic surgery, 99 2
A. Rimner, C. Simone, M. Zauderer, K. Cengel, V. Rusch (2016)
Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?The Lancet. Oncology, 17 2
Vishal Gupta, B. Mychalczak, L. Krug, R. Flores, M. Bains, V. Rusch, K. Rosenzweig (2005)
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.International journal of radiation oncology, biology, physics, 63 4
G. Zalcman, J. Mazières, J. Margery, L. Greillier, C. Audigier-Valette, D. Moro-Sibilot, O. Molinier, R. Corre, I. Monnet, V. Gounant, F. Rivière, H. Janicot, R. Gervais, C. Locher, B. Milleron, Q. Tran, M. Lebitasy, F. Morin, C. Créveuil, J. Parienti, A. Scherpereel (2016)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialThe Lancet, 387
S. Yajnik, K. Rosenzweig, B. Mychalczak, L. Krug, R. Flores, L. Hong, V. Rusch (2003)
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.International journal of radiation oncology, biology, physics, 56 5
A. Allen, M. Czerminska, P. Jänne, D. Sugarbaker, R. Bueno, J. Harris, L. Court, E. Baldini (2006)
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.International journal of radiation oncology, biology, physics, 65 3
L. Krug, H. Pass, V. Rusch, H. Kindler, D. Sugarbaker, K. Rosenzweig, R. Flores, J. Friedberg, K. Pisters, M. Monberg, C. Obasaju, N. Vogelzang (2009)
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 18
R. Stahel, O. Riesterer, A. Xyrafas, I. Opitz, M. Beyeler, A. Ochsenbein, M. Früh, R. Cathomas, K. Nackaerts, S. Peters, C. Mamot, A. Zippelius, C. Mordasini, C. Caspar, K. Eckhardt, R. Schmid, D. Aebersold, O. Gautschi, W. Nagel, M. Töpfer, J. Krayenbuehl, K. Ribi, I. Ciernik, W. Weder (2015)
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.The Lancet. Oncology, 16 16
P. Patel, S. Yoo, G. Broadwater, L. Marks, E. Miles, T. D’amico, D. Harpole, C. Kelsey (2012)
Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.International journal of radiation oncology, biology, physics, 83 1
A. Rimner, M. Zauderer, D. Gomez, P. Adusumilli, P. Parhar, A. Wu, K. Woo, R. Shen, M. Ginsberg, E. Yorke, D. Rice, A. Tsao, K. Rosenzweig, V. Rusch, L. Krug (2016)
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 23
D. Rice, W. Smythe, Z. Liao, T. Guerrero, Joe Chang, M. McAleer, M. Jeter, A. Correa, A. Vaporciyan, H. Liu, R. Komaki, K. Forster, C. Stevens (2007)
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.International journal of radiation oncology, biology, physics, 69 2
N. Vogelzang, J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffié, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, C. Niyikiza, P. Paoletti (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 14
E. Taioli, A. Wolf, M. Camacho-Rivera, Andrew Kaufman, Dong-Seok Lee, Daniel Nicastri, K. Rosenzweig, R. Flores (2015)
Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 PatientsPLoS ONE, 10
J Radiat Oncol (2017) 6:265–272 DOI 10.1007/s13566-017-0299-2 ORIGINAL RESEARCH Radiation therapy for localized malignant pleural mesothelioma: a propensity score-matched analysis of the National Cancer Data Base 1 2,3,4 2,3 4 5 Nisha Ohri & Emanuela Taioli & Bian Liu & Andrea Wolf & Jorge Gomez & 4 1 Raja Flores & Kenneth E. Rosenzweig Received: 20 December 2016 /Accepted: 3 March 2017 /Published online: 11 March 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract 5.3%, respectively; p < 0.001). In multivariable analysis and Objective The objectives of this study were to analyze rates of propensity matched analysis, definitive RT was significantly radiation therapy (RT) utilization for malignant pleural meso- associated with improved survival (adjusted hazard ratio [adj thelioma (MPM) and evaluate the association between RT and HR] 0.78, 95% CI 0.70–0.87) and (adj HR 0.77, 95% CI overall survival (OS). 0.67–0.89), respectively. Compared to no therapy, surgery Methods The National Cancer Data Base (NCDB) was que- and RT (adj HR 0.41, 95% CI 0.31–0.54) and trimodality ried to identify patients with non-metastatic MPM diagnosed therapy (adj HR 0.47, 95% CI 0.40–0.55) were associated between 2004 and 2013. RT was defined as receipt of 40- with the best survival. 65Gy of external
Journal of Radiation Oncology – Springer Journals
Published: Mar 11, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.